Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sangeetha M. Reddy | Researchclopedia

Back to researchers

Sangeetha M. Reddy

The University of Texas Southwestern Medical Center ORCID

118

Works

14,172

Citations

28

h-index

35

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research

Affiliations

Northwestern University2011–2013

United States Nuclear Regulatory Commission2020–2020

Shirley Ryan AbilityLab2012–2012

The University of Texas MD Anderson Cancer Center2015–2022

University of California, Los Angeles2010–2010

Top Works

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Vancheswaran Gopalakrishnan,Christine N. Spencer,et al.

20174,530 citations

Cancer Genomics and Diagnostics

Monoclonal and Polyclonal Antibodies Research

B cells and tertiary lymphoid structures promote immunotherapy response

Beth A. Helmink,Sangeetha M. Reddy,et al.

20202,555 citations

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman,Keren Yizhak,et al.

20181,986 citations

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Pei-Ling Chen,Whijae Roh,et al.

20161,004 citations

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Whijae Roh,Pei-Ling Chen,et al.

2017909 citations

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

Rodabe N. Amaria,Sangeetha M. Reddy,et al.

2018811 citations

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman,Keren Yizhak,et al.

2019347 citations

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Rodabe N. Amaria,Peter A. Prieto,et al.

2018286 citations

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Alexandre Reuben,Christine N. Spencer,et al.

2017187 citations